Medtronic PLC $MDT Stock Holdings Boosted by Journey Strategic Wealth LLC

Journey Strategic Wealth LLC lifted its position in Medtronic PLC (NYSE:MDT) by 274.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,635 shares of the medical technology company’s stock after buying an additional 6,329 shares during the period. Journey Strategic Wealth LLC’s holdings in Medtronic were worth $753,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MDT. 1248 Management LLC acquired a new position in Medtronic during the first quarter worth about $26,000. Twin Tree Management LP acquired a new position in shares of Medtronic in the 1st quarter worth approximately $29,000. Activest Wealth Management grew its stake in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares during the last quarter. Investment Management Corp VA ADV raised its holdings in shares of Medtronic by 144.2% in the 1st quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 238 shares in the last quarter. Finally, GFG Capital LLC acquired a new stake in Medtronic during the second quarter valued at approximately $36,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

MDT opened at $101.16 on Friday. The firm has a market capitalization of $129.76 billion, a P/E ratio of 27.87, a PEG ratio of 2.42 and a beta of 0.77. The stock has a fifty day moving average of $95.04 and a 200-day moving average of $90.88. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $102.59.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on MDT shares. Sanford C. Bernstein set a $111.00 price target on shares of Medtronic in a research report on Wednesday. Citigroup raised their price objective on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Barclays boosted their target price on Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday. UBS Group upped their target price on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Wells Fargo & Company lifted their price target on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $109.72.

Insiders Place Their Bets

In other news, Director William R. Jellison purchased 2,500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.